Human FCRN Alexa Fluor® 594-conjugated Antibody Summary
Accession # P55899
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
The neonatal Fc receptor (FCRN) is an approximately 45 kDa transmembrane glycoprotein with structural homology to MHC class I proteins. It is widely expressed in endothelial and epithelial cells and plays an important role in IgG homeostasis and antigen presentation by dendritic cells (1, 2). Mature human FCRN consists of a 274 amino acid (aa) extracellular domain (ECD) with two N-terminal alpha domains, one alpha 3/immunoglobulin-like domain, a 23 aa transmembrane segment, and a 44 aa cytoplasmic domain (3). Within the ECD, human FCRN shares 68% aa sequence identity with mouse and rat FCRN. Mouse FCRN binds with high affinity to IgG from mouse, human, rat, rabbit, guinea pig, bovine, and sheep, while human FCRN binds IgG with significantly lower affinity and is much more restricted in terms of species recognition (4). It does not bind the structurally related chicken IgY (5). FCRN additionally binds to albumin, and both it and IgG are bound at pH 5.0 but not at pH 8.0 (3, 6). FCRN associates noncovalently with beta 2-Microglobulin, and this interaction is important for the intracellular trafficking of FCRN (7-10). FCRN cycles between the plasma membrane and acidified intracellular compartments of endothelial cells and epithelial cells (5, 8). It binds endocytosed IgG and albumin in the low pH vesicles and transports them to the plasma membrane for extracellular release at higher pH. This protects IgG and albumin from lysosomal degradation and helps maintain the circulating levels of both proteins (5, 6). This mechanism is involved in the bidirectional transport of IgG across epithelial and endothelial barriers including neonatal IgG absorption in the intestine and fetal uptake of maternal antibodies through the placenta (5, 8, 11, 12). In the kidney, FCRN recycles albumin to the serum but removes IgG from the glomular basement membrane and promotes its excretion into the urine (13, 14). FCRN is also expressed in neutrophils and myeloid antigen presenting cells (7, 15, 16). It can enhance IgG-mediated phagocytosis and antigen presentation by these cells, but it promotes the degradation of opsonizing IgG rather than returning it to the circulation (15, 16).
- Baker, K. et al. (2009) Semin. Immunopathol. 31:223.
- Baker, K. et al. (2014) Front. Immunol. 5:408.
- Story, C.M. et al. (1994) J. Exp. Med. 180:2377.
- Ober, R.J. et al. (2001) Int. Immunol. 13:1551.
- Dickinson, B.L. et al. (1999) J. Clin. Invest. 104:903.
- Chaudhury, C. et al. (2003) J. Exp. Med. 197:315.
- Simister, N.E. and K.E. Mostov (1989) Nature 337:184.
- Kobayashi, N. et al. (2002) Am. J. Physiol. Renal Physiol. 282:F358.
- Praetor, A. and W. Hunziker (2002) J. Cell Sci. 115:2389.
- Zhu, X. et al. (2001) J. Immunol. 166:3266.
- Spiekermann, G.M. et al. (2002) J. Exp. Med. 196:303.
- Firan, M. et al. (2001) Int. Immunol. 13:993.
- Sarav, M. et al. (2009) J. Am. Soc. Nephrol. 20:1941.
- Akilesh, S. et al. (2008) Proc. Natl. Acad. Sci. 105:967.
- Vidarsson, G. et al. (2006) Blood 108:3573.
- Qiao, S.-W. et al. (2008) Proc. Natl. Acad. Sci. 105:9337.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human FCRN Alexa Fluor® 594-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human FCRN Alexa Fluor® 594-conjugated Antibody and earn rewards!
Have you used Human FCRN Alexa Fluor® 594-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image